Inclusion Criteria:  Men and premenopausal women with obesity defined as BMI ≥ 30 kg/m2 Upon the initiation of Liraglutide (within the first 1-4 weeks) for medical weight management, for clinical purposes, as advised by the primary physician Able to commit for a 6-month trial visits  Exclusion Criteria:  Pregnant women Patients who are taking or have taken other weight reducing drug therapies in the previous 6 months Patients who have undergone metabolic weight loss surgery Patients known to have diabetes (HbA1c ≥6.5% at screening) Patients with uncontrolled hypertension Patients with cardiac, pulmonary, renal or liver diseases, active cancer or psychiatric diseases Patients with excessive alcohol intake, defined as ≥ 2 glasses per day Patients known to have uncontrolled/ untreated thyroid disorders. Patients with cushing disease or polycystic ovaries, and those with neuro-endocrine or drug induced obesity (such as anti-psychotic, steroids, hormonal therapy): Such patients are resistant to weight loss, and they need treatment of their primary disease and/or cessation of the culprit medication to lose weight Patients with untreated gout Patients who have undergone bariatric surgery